

## **REMARKS**

### **Status of claims:**

Claims 1, 13-15, 17-34, 36-45, 48-50 and 63-73 were under examination. Claims 5-8 and 51-62 were withdrawn as drawn to non-elected inventions. No claims are amended herein.

### **Election:**

The Action imposed a restriction requirement between antibodies comprising CDR sequences SEQ ID NOs:7-12; SEQ ID NOs:13-18; SEQ ID NOs:30-35. Applicants assume that those SEQ ID NOs were inadvertently repeated and that the restriction also applies to antibodies comprising CDR sequences SEQ ID NOs:19-24; SEQ ID NOs:25-29; SEQ ID NOs:1-6 and SEQ ID NOs:36-41.

Applicants elect antibodies comprising a light chain variable region sequence comprising the CDR sequences KASQDVSIIVA (SEQ ID NO:7), SASYRYT ((SEQ ID NO:8) and QQHYITPLT (SEQ ID NO:9) and heavy chain variable region sequence comprising the CDR sequences NYGMN (SEQ ID NO:10), WINTYTGEPTYTDDFKG (SEQ ID NO:11) and GGFGSSYWFYDV (SEQ ID NO:12), found on the RS7 antibody. The election reads on claims 1, 5-8, 13-15, 17-22, 24, 26-34, 36-41, 43, 45, 48-52, 58 and 60-67.

Applicants respectfully assert that claims 1, 5-8, 13-15, 17-22, 24, 26-34, 36-41, 43, 45, 48-52, 58 and 60-66 are generic and understand that in the event a generic claim is found allowable, the remaining species will be considered under 37 C.F.R. §1.141.

Respectfully submitted,

/Richard A. Nakashima/  
By: Richard A. Nakashima  
Reg. No. 42,023  
Customer No.: 35657

Dated: January 14, 2007